Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors.

DuPre NC, Flavin R, Sfanos KS, Unger RH, To S, Gazeeva E, Fiorentino M, De Marzo AM, Rider JR, Mucci LA; Transdisciplinary Prostate Cancer Partnership(ToPCaP).

Prostate. 2018 Jul 15. doi: 10.1002/pros.23692. [Epub ahead of print]

PMID:
30009541
2.

Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.

Palsgrove DN, Li Y, Pratilas C, Lin MT, Pallavajjalla A, Gocke C, De Marzo AM, Matoso A, Netto GJ, Epstein JI, Argani P.

Am J Surg Pathol. 2018 Jul 3. doi: 10.1097/PAS.0000000000001111. [Epub ahead of print]

PMID:
29975249
3.

Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.

Yegnasubramanian S, De Marzo AM, Nelson WG.

Cold Spring Harb Perspect Med. 2018 Jun 29. pii: a030445. doi: 10.1101/cshperspect.a030445. [Epub ahead of print]

PMID:
29959132
4.

Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases.

Alharbi AM, De Marzo AM, Hicks JL, Lotan TL, Epstein JI.

Am J Surg Pathol. 2018 Jun 25. doi: 10.1097/PAS.0000000000001112. [Epub ahead of print]

PMID:
29944471
5.

Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate.

Markowski MC, Hubbard GK, Hicks JL, Zheng Q, King A, Esopi D, Rege A, Yegnasubramanian S, Bieberich CJ, De Marzo AM.

Prostate. 2018 May 30. doi: 10.1002/pros.23657. [Epub ahead of print]

PMID:
29851094
6.

Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer.

Kaur HB, Guedes LB, Lu J, Maldonado L, Reitz L, Barber JR, De Marzo AM, Tosoian JJ, Tomlins SA, Schaeffer EM, Joshu CE, Sfanos KS, Lotan TL.

Mod Pathol. 2018 May 30. doi: 10.1038/s41379-018-0083-x. [Epub ahead of print]

PMID:
29849114
7.

ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.

Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, De Marzo AM, Lotan TL.

Prostate. 2018 Sep;78(12):896-904. doi: 10.1002/pros.23646. Epub 2018 May 15.

PMID:
29761525
8.

Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer.

Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, Brennen WN, Marchionni L, Halushka MK, Lupold SE.

Sci Rep. 2018 May 8;8(1):7189. doi: 10.1038/s41598-018-25320-z.

9.

MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.

Bhanvadia RR, VanOpstall C, Brechka H, Barashi NS, Gillard M, McAuley EM, Vasquez JM, Paner G, Chan WC, Andrade J, De Marzo AM, Han M, Szmulewitz RZ, Vander Griend DJ.

Clin Cancer Res. 2018 May 1. doi: 10.1158/1078-0432.CCR-17-3673. [Epub ahead of print]

PMID:
29716922
10.

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.

Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.

PMID:
29577933
11.

Clinical implications of PTEN loss in prostate cancer.

Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL.

Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20. Review.

PMID:
29460925
12.

Diagnostic Utility of Cytokeratin-5 for the Identification of Proliferative Inflammatory Atrophy in the Canine Prostate.

Palmieri C, Story M, Lean FZX, Akter SH, Grieco V, De Marzo AM.

J Comp Pathol. 2018 Jan;158:1-5. doi: 10.1016/j.jcpa.2017.10.172. Epub 2017 Dec 1.

PMID:
29422309
13.

Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.

Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Mucci LA, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA.

Prostate. 2018 Feb;78(3):233-238. doi: 10.1002/pros.23462. Epub 2017 Nov 22.

PMID:
29164645
14.

Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression.

Valkenburg KC, De Marzo AM, Williams BO.

Oncotarget. 2017 May 17;8(46):80265-80277. doi: 10.18632/oncotarget.17919. eCollection 2017 Oct 6.

15.

Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides.

Baena-Del Valle JA, Zheng Q, Hicks JL, Fedor H, Trock BJ, Morrissey C, Corey E, Cornish TC, Sfanos KS, De Marzo AM.

Am J Clin Pathol. 2017 Nov 2;148(5):398-415. doi: 10.1093/ajcp/aqx094.

PMID:
29106457
16.

The inflammatory microenvironment and microbiome in prostate cancer development.

Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM.

Nat Rev Urol. 2018 Jan;15(1):11-24. doi: 10.1038/nrurol.2017.167. Epub 2017 Oct 31. Review.

PMID:
29089606
17.

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.

Markowski MC, De Marzo AM, Antonarakis ES.

Expert Opin Investig Drugs. 2017 Dec;26(12):1391-1397. doi: 10.1080/13543784.2017.1393518. Epub 2017 Oct 27. Review.

PMID:
29032717
18.

CXXC5 expression in prostate cancer: implications for cancer progression.

Benedetti I, De Marzo AM, Geliebter J, Reyes N.

Int J Exp Pathol. 2017 Aug;98(4):234-243. doi: 10.1111/iep.12241.

PMID:
29027288
19.

MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM.

J Pathol. 2018 Jan;244(1):11-24. doi: 10.1002/path.4980. Epub 2017 Nov 14.

20.

Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.

Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M, Wu X, Luo Y, Su N, Nava Rodrigues D, Figueiredo I, Welti J, Park E, Ma XJ, Coleman I, Morrissey C, Plymate SR, Nelson PS, de Bono JS, Luo J.

Eur Urol. 2018 May;73(5):727-735. doi: 10.1016/j.eururo.2017.08.009. Epub 2017 Sep 1.

PMID:
28866255
21.

Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer.

Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW, Sfanos KS.

J Urol. 2018 Jan;199(1):161-171. doi: 10.1016/j.juro.2017.08.001. Epub 2017 Aug 7.

22.

MSH2 Loss in Primary Prostate Cancer.

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL.

Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017 Aug 8.

PMID:
28790115
23.

A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts.

Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM.

Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1549-1557. doi: 10.1158/1055-9965.EPI-17-0503. Epub 2017 Jul 28.

24.

AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination.

Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, Schaeffer EM, Lotan TL, Isaacs WB, Netto GJ, De Marzo AM, Nelson WG, An SS, Yegnasubramanian S.

Nat Commun. 2017 Jul 26;8(1):142. doi: 10.1038/s41467-017-00084-8.

25.

Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.

Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM, Pomper MG, Allaf ME.

J Urol. 2018 Jan;199(1):126-132. doi: 10.1016/j.juro.2017.07.070. Epub 2017 Jul 20.

26.

Inflammation, Microbiota, and Prostate Cancer.

Puhr M, De Marzo A, Isaacs W, Lucia MS, Sfanos K, Yegnasubramanian S, Culig Z.

Eur Urol Focus. 2016 Oct;2(4):374-382. doi: 10.1016/j.euf.2016.08.010. Epub 2016 Aug 28. Review.

PMID:
28723469
27.

Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy.

Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Bachmann A, De Marzo AM, Robinson BD, Margulis V.

J Urol. 2017 Dec;198(6):1269-1277. doi: 10.1016/j.juro.2017.06.096. Epub 2017 Jul 12.

PMID:
28709887
28.

Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection.

Milbrandt M, Winter AC, Nevin RL, Pakpahan R, Bradwin G, De Marzo AM, Elliott DJ, Gaydos CA, Isaacs WB, Nelson WG, Rifai N, Sokoll LJ, Zenilman JM, Platz EA, Sutcliffe S.

Prostate. 2017 May;77(13):1325-1334. doi: 10.1002/pros.23392. Epub 2017 Jul 12.

29.

Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.

Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, Hofree M, Romanel A, Osborne JR, Kim JW, Azabdaftari G, Woloszynska-Read A, Sfanos K, De Marzo AM, Demichelis F, Gabriel S, Van Allen EM, Mesirov J, Tamayo P, Rubin MA, Powell IJ, Garraway LA.

Cancer Discov. 2017 Sep;7(9):973-983. doi: 10.1158/2159-8290.CD-16-0960. Epub 2017 May 17.

PMID:
28515055
30.

Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate.

Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT.

Oncotarget. 2017 Jul 18;8(29):46710-46727. doi: 10.18632/oncotarget.17362.

31.

Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.

Guedes LB, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, Netto GJ, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL.

Clin Cancer Res. 2017 Aug 15;23(16):4693-4703. doi: 10.1158/1078-0432.CCR-17-0257. Epub 2017 Apr 26.

PMID:
28446506
32.

Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.

Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA.

Prostate. 2017 Jun;77(8):908-919. doi: 10.1002/pros.23346. Epub 2017 Mar 20.

33.

Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.

Lotan TL, Torres A, Zhang M, Tosoian JJ, Guedes LB, Fedor H, Hicks J, Ewing CM, Isaacs SD, Johng D, De Marzo AM, Isaacs WB.

Oncotarget. 2017 Apr 4;8(14):22772-22782. doi: 10.18632/oncotarget.15196.

34.

Novel Assay to Detect RNA Polymerase I Activity In Vivo.

Guner G, Sirajuddin P, Zheng Q, Bai B, Brodie A, Liu H, Af Hällström T, Kulac I, Laiho M, De Marzo AM.

Mol Cancer Res. 2017 May;15(5):577-584. doi: 10.1158/1541-7786.MCR-16-0246. Epub 2017 Jan 23.

35.

Differential long-term stability of microRNAs and RNU6B snRNA in 12-20 year old archived formalin-fixed paraffin-embedded specimens.

Peskoe SB, Barber JR, Zheng Q, Meeker AK, De Marzo AM, Platz EA, Lupold SE.

BMC Cancer. 2017 Jan 6;17(1):32. doi: 10.1186/s12885-016-3008-4.

36.

Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization.

Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R.

Clin Cancer Res. 2017 Jun 15;23(12):3150-3157. doi: 10.1158/1078-0432.CCR-16-1490. Epub 2016 Dec 29.

37.

Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence.

Hempel HA, Cuka NS, Kulac I, Barber JR, Cornish TC, Platz EA, De Marzo AM, Sfanos KS.

Prostate. 2017 Mar;77(4):412-424. doi: 10.1002/pros.23280. Epub 2016 Nov 21.

PMID:
27868214
38.

Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.

Tosoian JJ, Almutairi F, Morais CL, Glavaris S, Hicks J, Sundi D, Humphreys E, Han M, De Marzo AM, Ross AE, Tomlins SA, Schaeffer EM, Trock BJ, Lotan TL.

Eur Urol. 2017 May;71(5):697-700. doi: 10.1016/j.eururo.2016.07.026. Epub 2016 Jul 28.

39.

Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial .

Kulac I, Gumuskaya B, Drake CG, Gonzalez B, Arnold KB, Goodman PJ, Kristal AR, Lucia MS, Thompson IM, Isaacs WB, De Marzo AM, Platz EA.

Prostate. 2016 Nov;76(15):1399-408. doi: 10.1002/pros.23224. Epub 2016 Jun 21.

40.

ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.

Morais CL, Guedes LB, Hicks J, Baras AS, De Marzo AM, Lotan TL.

Hum Pathol. 2016 Sep;55:117-25. doi: 10.1016/j.humpath.2016.04.017. Epub 2016 May 14.

41.

Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.

Guedes LB, Morais CL, Almutairi F, Haffner MC, Zheng Q, Isaacs JT, Antonarakis ES, Lu C, Tsai H, Luo J, De Marzo AM, Lotan TL.

Clin Cancer Res. 2016 Sep 15;22(18):4651-63. doi: 10.1158/1078-0432.CCR-16-0205. Epub 2016 May 10.

42.

PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.

Trock BJ, Fedor H, Gurel B, Jenkins RB, Knudsen BS, Fine SW, Said JW, Carter HB, Lotan TL, De Marzo AM.

Mod Pathol. 2016 Jul;29(7):764-71. doi: 10.1038/modpathol.2016.63. Epub 2016 Apr 15.

43.

In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.

Picanço-Albuquerque CG, Morais CL, Carvalho FL, Peskoe SB, Hicks JL, Ludkovski O, Vidotto T, Fedor H, Humphreys E, Han M, Platz EA, De Marzo AM, Berman DM, Lotan TL, Squire JA.

Virchows Arch. 2016 May;468(5):607-17. doi: 10.1007/s00428-016-1904-2. Epub 2016 Feb 9.

PMID:
26861919
44.

Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants.

Padmanabhan A, Rao V, De Marzo AM, Bieberich CJ.

Prostate. 2016 May;76(6):523-33. doi: 10.1002/pros.23144. Epub 2016 Feb 4. Review.

PMID:
26841725
45.

Ki-67 is required for maintenance of cancer stem cells but not cell proliferation.

Cidado J, Wong HY, Rosen DM, Cimino-Mathews A, Garay JP, Fessler AG, Rasheed ZA, Hicks J, Cochran RL, Croessmann S, Zabransky DJ, Mohseni M, Beaver JA, Chu D, Cravero K, Christenson ES, Medford A, Mattox A, De Marzo AM, Argani P, Chawla A, Hurley PJ, Lauring J, Park BH.

Oncotarget. 2016 Feb 2;7(5):6281-93. doi: 10.18632/oncotarget.7057.

46.

Premalignancy in Prostate Cancer: Rethinking What we Know.

De Marzo AM, Haffner MC, Lotan TL, Yegnasubramanian S, Nelson WG.

Cancer Prev Res (Phila). 2016 Aug;9(8):648-56. doi: 10.1158/1940-6207.CAPR-15-0431. Epub 2016 Jan 26. Review.

47.

Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial.

Winchester DA, Gurel B, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Thompson IM, Xu J, Zheng SL, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, Drake CG, De Marzo AM, Platz EA.

Prostate. 2016 May;76(6):565-74. doi: 10.1002/pros.23147. Epub 2016 Jan 15.

48.

Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.

Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM Jr, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):463-9. doi: 10.1158/1055-9965.EPI-15-0987. Epub 2015 Dec 29.

49.

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection.

Sutcliffe S, Nevin RL, Pakpahan R, Elliott DJ, Langston ME, De Marzo AM, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Walsh PC, Zenilman JM, Cersovsky SB, Platz EA.

Int J Cancer. 2016 May 1;138(9):2221-30. doi: 10.1002/ijc.29966. Epub 2016 Jan 21.

50.

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL.

J Natl Cancer Inst. 2015 Nov 27;108(2). pii: djv346. doi: 10.1093/jnci/djv346. Print 2016 Feb.

Supplemental Content

Loading ...
Support Center